Gain insights from our experts...
Optimizing lipid nanoparticles (LNPs) processing for siRNA delivery by microfluidics system
The success of mRNA vaccines during the COVID-19 pandemic has accelerated the advancement of nucleic acid delivery technologies. In addition to mRNA, interfering RNA offers potential to treat diseases beyond the reach of small molecules. However, therapeutic success hinges on efficient and targeted delivery systems. Lipid nanoparticles (LNPs), especially those produced via microfluidics, have emerged as a leading platform for RNA delivery. delivery. for RNA.
Join Dr. Qiaobin Hu as he explores LNP formulation for siRNA delivery using a microfluidic flow-focusing system.
Optimising lipid nanoparticles (LNPs) processing for siRNA delivery by microfluidics system
866.3 KB
Explore our poster presentation with Qiaobin Hu
Explore additional content
recent insights:
Experience Croda Pharma in Action at CPHI Europe 2026
At CPHI Europe 2026, we’re bringing the refreshed Croda Pharma brand to life. Our new identity reflects our continued commitment to innovation and partnership, with a focus on helping customers...
Different Regulatory Approaches to Excipient Requirements: The Case of EG/DEG Contamination Risk in Pharmaceuticals
Dr. Miquel Mir, Pharma Regulatory Mgr, just published the article “Different Regulatory Approaches to Excipient Requirements: The Case of EG/DEG Contamination Risk in Pharmaceuticals“ in the...
Liposomal generics in Asia: Supporting scalable drug delivery through GMP lipid excellence
Across Asia, healthcare systems are balancing rising disease burden, expanding access expectations, and increasing cost pressures, making generic medicines central to national healthcare strategies